Alirocumab: Pediatric First Approval
Pediatric Drugs · 2024
DOI: 10.1007/s40272-024-00637-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Drugs, 2024. Verfasst von Connie Kang. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. pdd@adis.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Alirocumab (Praluent®), a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor that has been co-developed by Regeneron Pharmaceuticals, Inc. and Sanofi (formerly sanofi-aventis), is approved globally for use in adults with established cardiovascular disease, primary hyperlipidemia [including heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH)]. In November 2023, based on clinical data in patients aged 8-17 years, alirocumab received its first pediatric approval in the EU as an adjunct to diet alone, or in combination with a statin and/or other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in pediatric patients aged ≥ 8 years with HeFH. Alirocumab was approved a few months later in the US for use as an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged ≥ 8 years with HeFH to reduce LDL-C. This article summarizes the milestones in the development of alirocumab leading to this first pediatric approval for HeFH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. pdd@adis.com.
Zitieren
APA
Kang, C. (2024). Alirocumab: Pediatric First Approval. Pediatric Drugs. https://doi.org/10.1007/s40272-024-00637-7
Vancouver
Kang C. Alirocumab: Pediatric First Approval. Pediatric Drugs. 2024. doi:10.1007/s40272-024-00637-7
BibTeX
@article{Kang2024,
author = {Kang, Connie},
title = {Alirocumab: Pediatric First Approval},
journal = {Pediatric Drugs},
year = {2024},
doi = {10.1007/s40272-024-00637-7}
}
EUVIMED